BS_ZZPBANDD
DNET
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- DNET
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- DNET
- age_years
- 11.066
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.526
- NOTCH_SIGNALING+0.372
- ADIPOGENESIS+0.313
- FATTY_ACID_METABOLISM+0.281
- KRAS_SIGNALING_DN+0.280
- HEDGEHOG_SIGNALING+0.278
- APICAL_SURFACE+0.252
- PANCREAS_BETA_CELLS+0.242
- ESTROGEN_RESPONSE_EARLY+0.215
- MYOGENESIS+0.207
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.421
- E2F_TARGETS-0.368
- MYC_TARGETS_V1-0.356
- IL6_JAK_STAT3_SIGNALING-0.352
- UNFOLDED_PROTEIN_RESPONSE-0.310
- INTERFERON_GAMMA_RESPONSE-0.307
- G2M_CHECKPOINT-0.290
- DNA_REPAIR-0.278
- IL2_STAT5_SIGNALING-0.242
- INFLAMMATORY_RESPONSE-0.214
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_AD4JPN9Q | Ganglioglioma | — | 0.847 |
| 2 | SRR1418837 | GTEX | — | 0.832 |
| 3 | BS_KZPR01BD | DNET | — | 0.806 |
| 4 | BS_VMMJYN8Z | Ganglioglioma | — | 0.803 |
| 5 | BS_E4QK839R | low-grade glioma | — | 0.800 |
| 6 | GSM6454744 | — | A | 0.798 |
| 7 | BS_CVGFNCBJ | low-grade glioma | — | 0.798 |
| 8 | BS_CGB2WS2A | pilocytic astrocytoma | — | 0.788 |
| 9 | SRR818418 | GTEX | — | 0.784 |
| 10 | SRR1457482 | GTEX | — | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.526 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.372 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.313 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.281 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.278 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.252 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.242 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.215 | Inavolisib | — uncovered |
| MYOGENESIS | 0.207 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.201 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.182 | Inavolisib | — uncovered |
| PEROXISOME | 0.141 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.127 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.127 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.096 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.057 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.056 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.039 | Inavolisib | — uncovered |